Teleflex Incorporated (TFX) Stock Analysis & Winston Score
Teleflex makes medical devices used by doctors and nurses in hospitals around the world. Its most well-known products include vascular access catheters, surgical instruments, and the UroLift system, which treats an enlarged prostate without major surgery. The company sells primarily to hospitals, clinics, and healthcare systems across more than 140 countries. Teleflex earns most of its revenue by selling single-use disposable medical devices, which means hospitals reorder supplies on a regular basis. It operates globally, with significant sales in North America and Europe, and generates roughly $3 billion in annual revenue. The company's competitive position relies on specialized products that require clinical training to use, creating some switching costs, but its relatively low ROIC and operating margin suggest heavy debt from past acquisitions weighs on profitability. The key growth driver is continued adoption of the UroLift system in a large and underpenetrated urology market, while pricing pressure from hospital purchasing groups remains an ongoing risk.
Winston Score: 24/100 — Weak
Weak fundamentals across most pillars.
- Quality: Mixed (11/30)
- Growth: Weak (2/20)
- Cash Flow: Weak (2/10)
- Stability: Good (6/10)
- Valuation: Data not available (0/10)
- Ownership: Weak (2/15)
Key Facts
Price: $134.61
Market Cap: $6.0B
Sector: Healthcare
Industry: Medical - Instruments & Supplies


